Pfizer's experimental 'abuse-deterrent' opioid under FDA review
This article was originally published in Scrip
Executive Summary
The FDA has accepted Pfizer's new drug application for its ALO-02, an extended-release combination of oxycodone hydrochloride and naltrexone hydrochloride, which is formulated in a way intended to deter abuse via snorting and intravenous (IV) routes when crushed.